Lachey Jennifer 4
4 · Keros Therapeutics, Inc. · Filed May 13, 2022
Insider Transaction Report
Form 4
Lachey Jennifer
Chief Scientific Officer
Transactions
- Exercise/Conversion
Common Stock
2022-05-11$0.30/sh+5,300$1,590→ 91,000 total - Sale
Common Stock
2022-05-11$41.26/sh−3,398$140,201→ 87,602 total - Sale
Common Stock
2022-05-11$42.49/sh−944$40,111→ 86,658 total - Sale
Common Stock
2022-05-11$43.32/sh−719$31,147→ 85,939 total - Sale
Common Stock
2022-05-11$44.23/sh−223$9,863→ 85,716 total - Sale
Common Stock
2022-05-11$45.45/sh−16$727→ 85,700 total - Exercise/Conversion
Employee Stock Option (right to buy)
2022-05-11−5,300→ 66,105 totalExercise: $0.30Exp: 2028-03-25→ Common Stock (5,300 underlying)
Footnotes (7)
- [F1]The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan.
- [F2]The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $40.915 to $41.88 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnotes (2), (3), (4), (5) and (6).
- [F3]The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $41.915 to $42.90 inclusive.
- [F4]The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $43.04 to $43.62 inclusive.
- [F5]The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $44.075 to $44.43 inclusive.
- [F6]The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $45.31 to $45.46 inclusive.
- [F7]Immediately exercisable.